Lorlatinib for ALK-fused, infant-type hemispheric glioma with lung metastasis: a case report

Ann Clin Transl Neurol. 2023 May;10(5):836-841. doi: 10.1002/acn3.51766. Epub 2023 Mar 31.

Abstract

Infant-type hemispheric glioma, a new subtype of pediatric high-grade glioma, arises in the cerebral hemispheres. Despite better survival outcomes, the treatment of infant-type hemispheric glioma is still facing challenges. Here, we reported a case of QKI-ALK fusion, infant-type hemispheric glioma with lung metastasis who achieved a complete clinical response after lorlatinib treatment. This typical case demonstrated the importance of appropriate molecularly targeted treatments in ALK-fused tumors, and lorlatinib may serve as an effective complement to conventional chemotherapy and radiotherapy in primary glioma harboring ALK fusions and its metastasis.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anaplastic Lymphoma Kinase / therapeutic use
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Child
  • Glioma* / drug therapy
  • Humans
  • Infant
  • Lactams, Macrocyclic / therapeutic use
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / pathology
  • Protein Kinase Inhibitors

Substances

  • lorlatinib
  • Anaplastic Lymphoma Kinase
  • Protein Kinase Inhibitors
  • Lactams, Macrocyclic

Grants and funding

This work was funded by Study on the correlation between the characteristic genes of different molecular subgroups and tumor microenvironment in glioblastoma multiforme grant 202201011741.